CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 050680/S002

PHARMACOLOGY REVIEW(S)

Review and Evaluation of Pharmacology and Toxicology Data
Division of Anti-Infective Drug Products, HFD-520

NDA #: 50,680 S-002

SPONSOR: The Upjohn Company
7000 Portage Road
Kalamazoo, MI 49001-0199

AUTHORIZED REPRESENTATIVE: Donald A. Egge, Director
Worldwide Regulatory Affairs-Marketed Products
(616) 329-8097; FAX (616) 329-5409

DRUG NAMES: Cleocin® Vaginal Cream; clindamycin phosphate 2%; Dalacin™; 7(s)-Chloro-7-Deoxylincomycin-2-Phosphate

CATEGORY: Semi-synthetic derivative of lincomycin

STRUCTURAL FORMULA:



Clindamycin Phosphate

RELATED SUBMISSIONS:

NUMBER OF VOLUMES: 1

DATE CDER RECEIVED: 6/2/95

DATE ASSIGNED: 6/5/95

DATE REVIEW STARTED: 6/6/95

DATE 1ST DRAFT COMPLETED: 6/7/95

DATE REVIEW ACCEPTED BY SUPERVISOR: June 14, 1995

REVIEW OBJECTIVES: To determine whether the existing Pharm/Tox data in this NDA supports the new 3-day dosing regimen proposed by the sponsor.

DOSAGE FORM AND ROUTE OF ADMINISTRATION:

Clindamycin (2%) in a cream base consisting of benzyl alcohol, cetostearyl alcohol, cetyl palmitate, mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate, and stearic acid. An applicator full of cream (5 g product containing 100 mg clindamycin) is applied intravaginally once per day, preferably at bedtime.

PRECLINICAL PHARMACOLOGY/TOXICOLOGY:

This application contains no pharmacology or toxicology studies, and none are necessary. The cream will continue to be identical to the approved product that is presently being marketed. The purpose of this submission is to gain approval for a treatment duration of as few as 3 days. The current recommended length of treatment is 7 days.

For reference purposes, a copy of the Pharm/Tox review for this NDA is attached, as well as a memo regarding pregnancy labeling and reproductive toxicity studies of clindamycin.

SUMMARY AND EVALUATION:

There are no Pharm/Tox issues present in this supplement. The proposed length of treatment is as few as 3 days, as opposed to the current 7. Thus, exposure to the drug will be reduced in some patients if this application is approved. The Pharm/Tox data in the original NDA supported a 7 day treatment, consequently they are adequate to support a shorter duration of exposure at the same dosage level.

RECOMMENDATION:

I have no objection to the approval of this NDA supplement from the Pharm/Tox standpoint.

/S/

Amy L. Ellis, Ph.D.
Pharmacologist, HFD-520

Orig. IND
cc:
HFD-520
HFD-520/Sup Pharm/Osterberg
HFD-520/Pharm/Ellis
HFD-520/MO/Winfield
HFD-520/Chem/
HFD-520/CSO/Chi
HFD-520/Micro/

Concurrence Only:
HFD-520/REOsterberg 1/31/6/14/95
HFD-520/LGavrilovich

Note: Product contains mineral oil. Cautionary statement regarding use of latex condoms should be present in labeling.

/S/

APPEARS THIS WAY
ON ORIGINAL